Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
NCT07691450Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Jan 2027
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of belinostat in T-cell lymphoma (2 arms), sponsored by City of Hope. Primary endpoints: Dose-Limiting Toxicities and Maximum Tolerated Dose. Planned start Jan 2027; status: recruiting.
02
Drugs
belinostat
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT07691450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691450.